Chikungunya virus Vaccine / Merck (MSD) - LARVOL DELTA

Mapping Human Clinical Evidence for Chikungunya Vaccines: A Scoping Review of Immunogenicity, Durability, and Safety. (PubMed, Vaccines (Basel)) - "The included evidence clustered around a limited number of vaccine programs, including TSI-GSD-218, VRC-CHKVLP059-00-VP/PXVX0317/Vimkunya, MV-CHIK/V184, VLA1553/IXCHIQ, ChAdOx1 Chik, and mRNA-1388/VAL-181388. Short-term trial safety data were characterized primarily by mild or moderate local and systemic reactogenicity, while post-authorization safety evidence remains recent and concentrated in licensed products. This scoping review provides a structured evidence map for CHIKV vaccine development and highlights priorities for standardized immunogenicity assessment, longer-term durability data, broader population representation, endemic-region effectiveness studies, and continued post-marketing surveillance."

Journal • Review • Chikungunya

A measles virus-based vaccine induces robust chikungunya virus-specific CD4 T-cell responses in a phase II clinical trial. (PubMed, Vaccine) - "CHIKV-specific CD8 T-cells induced by MV-CHIK vaccination were inconsistently detected. Our data show that the MV-CHIK vector vaccine induced a functional transgene-specific CD4 T cell response which, together with the evidence of neutralizing antibodies as correlate of protection for CHIKV, makes MV-CHIK a promising vaccine candidate in the prevention of chikungunya."

Journal • P2 data • Chikungunya • Infectious Disease • Measles • Musculoskeletal Pain • CD4 • CD8

Antibody effector analysis of prime versus prime-boost immunizations with a recombinant measles-vectored chikungunya virus vaccine. (PubMed, JCI Insight) - "Nonetheless, antibody avidity and ADCP remained significantly greater following boost immunization. Our observations suggest that a prime-boost administration of MV-CHIK will be more appropriate for CHIKV-endemic regions, while a prime only regimen may be sufficient for travel purposes or outbreak situations."

Journal • Chikungunya • Immunology • Infectious Disease

Chikungunya Vaccine Study in Previously Exposed Adults (V184-006) (clinicaltrials.gov) - P2; N=41; Completed; Sponsor: Themis Bioscience GmbH; Suspended ➔ Completed; N=60 ➔ 41

Enrollment change • Trial completion • Chikungunya • Infectious Disease